Request a rep

CONFIDENCE IN COVERAGE

90% of Commercial Patients are covered
88% of Medicare Part D patients are covered
86% of Medicare Part D patients have unrestricted access

Most Medicare Part D patients have unrestricted access to RESTASIS®1†

Are your patients getting the #1 dispensed branded eye drop when filled?

Preferred or covered status for the majority of patients2*

Commercial Payers2*

National average co-pay for 30 days: $44.85

National average co-pay for 90 days: $66.97

Part D Payers2*

National average co-pay for 30 days: $29.42

National average co-pay for 90 days: $60.70

90% of commercial and 88% Part D patients are covered for RESTASIS® as of April 20231

89% of Medicare Part D patients have unrestricted access1†

Eligible patients pay

AS LITTLE AS $0^

for a 90-day supply of RESTASIS® single-use vials or 3 bottles of RESTASIS MultiDose®

^Patient out-of-pocket costs may vary. Terms and conditions apply. This offer is only valid for commercially insured patients. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see full Program Terms, Conditions, and Eligibility Criteria here.

Enroll your patients

FOR PATIENTS EXPERIENCING FINANCIAL HARDSHIP OR WITH LIMITED OR NO COVERAGE

Contact the My Tears, My Rewards® Program by calling the toll-free customer service support line 1-844-4MY-TEARS
(1-844-469-8327)

Contact the My Tears, My Rewards® Program by calling the toll-free customer service support line 1-844-4MY-TEARS
(1-844-469-8327)

LEARN MORE

get dedicated prior authorization (PA) support through CoverMyMeds® and PARx Solutions®

Need help with a patient’s PA?

CoverMyMeds

1-866-452-5017

Visit CoverMyMeds

M-F: 8:00 AM–11:00 PM ET
Sat: 8:00 AM–6:00 PM ET

PARx Solutions®

1-866-725-7279

Visit PARx Solutions

ACCESS & IN-OFFICE TOOLS

Co-Pay Flashcard

Understand how much patients may be able to save on their RESTASIS® prescription based on their insurance plans.

Download co-pay flashcard
Download

Access Flashcard

Confidence in coverage—find additional information here on patient access to RESTASIS®.

Download access flashcard

PATIENT RESOURCES

Patient Brochure

Help patients understand what to expect from treatment with RESTASIS®, including clear and simple instructions for use.

Download patient brochure
Download patient brochure
Download

Want to learn more about RESTASIS®?

Request a rep visit.

Request a visit from a RESTASIS® representative for tailored support and advice.

Request a rep

Visit TechAlliance to stay up to date with the latest in eye care

TechAlliance is a resource hub designed to help ophthalmic technicians and their office staff deliver optimal eye care.

At TechAlliance you can find:

  • Downloadable product information and resources
  • Training tutorials covering common issues in managed care and pharmacy
  • Clinical and educational tools for various eye care conditions
  • Patient resources, including financial assistance programs
join the alliance

EFFICACY & SAFETY

Experience the evidence of RESTASIS®, including safety and tolerability.

LEARN MORE

Dosing

One drop, twice a day, every day.

LEARN MORE

INDICATIONS AND USAGE

RESTASIS® and RESTASIS MultiDose® ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

RESTASIS® and RESTASIS MultiDose® are contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

WARNINGS AND PRECAUTIONS

POTENTIAL FOR EYE INJURY AND CONTAMINATION: Be careful not to touch the container tip to your eye or other surfaces to avoid potential for eye injury and contamination.

USE WITH CONTACT LENSES: RESTASIS® and RESTASIS MultiDose® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS® and RESTASIS MultiDose® ophthalmic emulsion.

ADVERSE REACTIONS:

In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see Full Prescribing Information

*Source: Symphony Health Managed Markets Vantage, November 2018 - October 2019. Data are subject to change. Data are not a guarantee of coverage, or partial or full payment, by any payers. Actual benefits determined by respective plan administrators, insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. Allergan does not endorse any individual plans. Formulary coverage does not imply efficacy or safety. 

†Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with the applicable insurer. Allergan does not endorse any individual plans. Formulary coverage comparisons are not intended to imply a comparison of efficacy, safety, therapeutic equivalence, or overall cost of care.

1. Managed Market Insights & Technology, LLCTM, a trademark of MMIT Database, as of February 2021. 2. Managed Market Insights & Technology, LCCTM, a trademark of MMIT Database, as of October 2019.

US-REST-210087

IMPORTANT SAFETY INFORMATION

Do not use RESTASIS® and RESTASIS MultiDose® Ophthalmic Emulsion if you are allergic to any of the ingredients. Be careful not to touch the container tip to your eye or other surfaces, to help avoid eye injury and contamination. RESTASIS® and RESTASIS MultiDose® should not be used while wearing contact lenses. If contact lenses are worn, they should be removed prior to use of RESTASIS® and RESTASIS MultiDose® and may be reinserted after 15 minutes.

INDICATIONS AND USAGE

RESTASIS® and RESTASIS MultiDose® ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

IMPORTANT SAFETY INFORMATION

Do not use RESTASIS® and RESTASIS MultiDose® Ophthalmic Emulsion if you are allergic to any of the ingredients. Be careful not to touch the container tip to your eye or other surfaces, to help avoid eye injury and contamination. RESTASIS® and RESTASIS MultiDose® should not be used while wearing contact lenses. If contact lenses are worn, they should be removed prior to use of RESTASIS® and RESTASIS MultiDose® and may be reinserted after 15 minutes.

INDICATIONS AND USAGE

RESTASIS® and RESTASIS MultiDose® ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

INDICATIONS AND USAGE

RESTASIS® and RESTASIS MultiDose® ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

RESTASIS® and RESTASIS MultiDose® are contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

WARNINGS AND PRECAUTIONS

POTENTIAL FOR EYE INJURY AND CONTAMINATION: Be careful not to touch the container tip to your eye or other surfaces to avoid potential for eye injury and contamination.

USE WITH CONTACT LENSES: RESTASIS® and RESTASIS MultiDose® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS® and RESTASIS MultiDose® ophthalmic emulsion.

ADVERSE REACTIONS:

In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see Full Prescribing Information

*Source: Symphony Health Managed Markets Vantage, November 2018 - October 2019. Data are subject to change. Data are not a guarantee of coverage, or partial or full payment, by any payers. Actual benefits determined by respective plan administrators, insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. Allergan does not endorse any individual plans. Formulary coverage does not imply efficacy or safety. 

†Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with the applicable insurer. Allergan does not endorse any individual plans. Formulary coverage comparisons are not intended to imply a comparison of efficacy, safety, therapeutic equivalence, or overall cost of care.